America's #1 Medical Device Regulatory Consultancy
Why Choose Us?
- Extensive expertise in global regulations for medical devices.
- Personalized approach tailored to your specific needs.
- Timely and efficient certification support.
- In-depth knowledge of MDSAP requirements.
- State-of-the-art testing facilities and experienced team.
- Commitment to ensuring the safety and compliance of your products.
Our Services
For manufacturers looking to expand their market reach, compliance with the MDSAP becomes essential.
Navigating the complex landscape of regulatory certifications can be challenging.
At Safetek Regulatory Services, we understand the significance of safety and biocompatibility testing for medical devices.
If you are seeking to market your medical devices in Australia, our consultancy organization offers Australian sponsor services.
Managing regulatory correspondence can be a challenging task. Our consultancy organization offers professional support.
Our Team
- Regulatory Specialists
- Quality Assurance Professionals
- Medical Device Experts
- Internal Auditors
- Accredited Testing Laboratory Partners
- Software Solutions
Join Our Team and Make a Difference in the Medical Device Regulatory Field
- Excellence
- Collaboration
- Customer Focus
- Innovation
- Integrity
Our Experts
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Lorem Ipsum
CEO
Articles & Insights
Updated few moments ago...
Cybersecurity in Medical Devices: Where…
A few years ago, a hospital network discovered that one of its connected infusion pump systems could be accessed remotely without authentication. The issue was not immediately exploited, but the implication was clear: unauthorized access could alter dosage delivery. What began as a “technical vulnerability” quickly escalated into a regulatory concern and, more importantly, a legal risk with patient safety at its core. This is the reality of modern medical devices. Connectivity brings clinical benefits—but also creates exposure that sits squarely at the intersection of regulatory compliance and legal accountability. Regulatory Expectations Are No Longer Optional From a U.S. regulatory perspective, cybersecurity is no longer treated as an ancillary IT concern. The FDA has made it clear that cybersecurity is part of device safety and effectiveness. Premarket expectations now require manufacturers to demonstrate that cybersecurity risks are identified, assessed, and controlled as part of design controls. This includes secure architecture, threat modeling, software bill of materials (SBOM), and plans for ongoing updates. Postmarket, the FDA expects continuous monitoring, vulnerability management, coordinated disclosure practices, and timely remediation. The 2023 FDA Refuse-to-Accept (RTA) policy update for cybersecurity submissions reinforced that incomplete cybersecurity documentation can delay or block market access. For regulatory teams, this means cybersecurity must be integrated into: – Design controls under 21 CFR Part 820 – Risk management aligned with ISO 14971 – Software lifecycle processes (IEC 62304 principles) – Post-market surveillance systems Cybersecurity is no longer a “nice-to-have appendix” in technical documentation. It is part of the core safety case. When Regulatory Gaps Become Legal Exposure Where this becomes more complex—and often underestimated—is how cybersecurity failures translate into legal liability. If a vulnerability leads to patient harm, the legal system does not distinguish between a mechanical defect and a software exploit. Both can trigger product liability claims. Several legal theories may apply: – Design defect: Failure to incorporate reasonable cybersecurity controls during development – Failure to warn: Not informing users about known vulnerabilities or required mitigations – Negligence: Lack of reasonable care in monitoring, patching, or responding to known threats – Breach of warranty: Claims that the device was not “safe” or “fit for use” as represented In the U.S., plaintiffs’ attorneys are increasingly exploring cybersecurity angles, particularly in cases involving connected devices. Even without widespread harm, regulatory findings—such as FDA warning letters—can be used as evidence of non-compliance in civil litigation. One illustrative example involved a class of implantable cardiac devices where vulnerabilities were identified postmarket. Although no confirmed patient injuries occurred, the manufacturer faced regulatory scrutiny, issued safety communications, and undertook a large-scale software update program. The cost was not just operational—it included reputational damage and increased legal exposure. In another case, a hospital system raised concerns about outdated software in networked imaging systems. While the manufacturer had issued patches, delays in deployment and lack of clear communication created ambiguity around responsibility—opening the door to potential liability disputes between manufacturers and users. The Disconnect Between Engineering, Regulatory, and Legal One recurring issue I see in practice is fragmentation. Engineering teams focus on technical mitigation. Regulatory teams focus on submission requirements. Legal teams engage only when something goes wrong. Cybersecurity risks do not respect these silos. A vulnerability left unaddressed is not just a technical gap—it may represent: – A failure in risk management documentation – A deviation from declared design controls – A breach of post-market obligations – A potential argument for negligence in court The legal exposure often depends not only on the vulnerability itself, but on how well the company can demonstrate that it acted responsibly, proactively, and transparently. Documentation, therefore, becomes critical—not just for auditors, but for attorneys. Practical Implications for Leadership For senior management, cybersecurity should be treated as a governance issue, not just a technical function. A few practical considerations: First, ensure cybersecurity is embedded early in product development. Retrofitting controls postmarket is significantly more expensive—and harder to defend legally. Second, align risk management with real-world threat scenarios. Traditional hazard analysis is not enough; threat modeling must be part of the process. Third, establish a clear vulnerability disclosure and response framework. How quickly can your organization assess, communicate, and remediate a newly discovered issue? Fourth, maintain traceability. If challenged—by regulators or in court—you should be able to demonstrate what was known, when it was known, and what actions were taken. Finally, do not underestimate communication. Safety notices, field actions, and software updates must be timely, clear, and well-documented. Ambiguity creates legal risk. Closing Perspective Cybersecurity in medical devices is no longer just about protecting systems—it is about protecting patients, regulatory standing, and corporate liability simultaneously. Organizations that treat cybersecurity as a compliance checkbox are exposing themselves to far more than audit findings. They are risking recalls, enforcement actions, and litigation that can be far more damaging than the original vulnerability. The companies that will navigate this successfully are those that integrate cybersecurity into their regulatory strategy and legal thinking from the outset—not as a reaction, but as a core element of product responsibility. Here are 10 high-value, insight-driven FAQs you can append to the blog, tailored for senior regulatory, technical, and legal audiences: ——————————– FAQs on Cybersecurity in Medical Devices ——————————– 1. Is cybersecurity explicitly required by the FDA, or is it still considered guidance-driven? While much of FDA cybersecurity content originated as guidance, recent legislative updates (e.g., FD&C Act Section 524B) have made cybersecurity requirements enforceable for certain devices. In practice, failure to meet these expectations can result in refusal-to-accept decisions or enforcement actions. 2. Can a cybersecurity vulnerability alone trigger a product recall? Yes. If a vulnerability presents a reasonable probability of patient harm, it can lead to a recall—even without confirmed adverse events. FDA has already classified cybersecurity-related recalls based on potential risk severity. 3. How does cybersecurity tie into design controls under 21 CFR Part 820? Cybersecurity must be addressed as part of design inputs, verification, validation, and risk control measures. If it is not embedded within design controls, the product may be considered inherently defective from
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
